Federal Circuit Rejects Pharma Company’s Attempt to Refile Suit to Reset Deadline

By Editorial Team

The Federal Circuit recently ruled against Ascendis Pharma’s efforts to refile a lawsuit in order to reset a missed deadline related to a mandatory stay in California federal court. The company had sought to invoke a mandatory stay based on parallel U.S. International Trade Commission proceedings, but the court determined that the attempt to reset the patent litigation deadline was not permissible.

Ascendis Pharma’s case involved a missed opportunity to utilize a mandatory stay in California federal court due to ongoing proceedings at the U.S. International Trade Commission. Despite attempting to reset the deadline through refiling the lawsuit, the Federal Circuit rejected this strategy, indicating that the missed window for invoking the mandatory stay could not be circumvented.

The decision by the Federal Circuit serves as a reminder of the importance of adhering to procedural deadlines in patent litigation cases. Companies involved in such disputes must carefully manage their legal strategies and timelines to avoid missing crucial opportunities for invoking stays or other procedural mechanisms.

The ruling by the Federal Circuit underscores the significance of procedural rules and the consequences of missing key deadlines in patent litigation. It also highlights the complexities involved in navigating parallel proceedings in different legal venues and the challenges companies may face in coordinating their legal strategies effectively.

Overall, the case serves as a cautionary tale for pharmaceutical companies and other entities engaged in patent litigation, emphasizing the need for meticulous planning and adherence to procedural requirements to avoid potential setbacks and missed opportunities in legal proceedings.